Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05373771 · ClinicalTrials.gov registry record · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
A NA study of Sickle Cell Crisis, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- NA
- Development phase
- 5,328
- Enrollment target
- 1
- Study location
NCT05373771: Recruiting NA study of Sickle Cell Crisis, sponsored by Medical College of Wisconsin.
NCT05373771 is a NA study of Sickle Cell Crisis that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 5,328 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (279% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05373771, a NA study of Sickle Cell Crisis, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- NA
- Development phase
- 5,328 participants
- Enrollment target
- 1
- Study location
Study Summary
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.
Primary Outcome
The percent of patients who receive first dose of opioids within 60 minutes of arrival and subsequent doses within 30 minutes of previous dose
Conditions Studied
Interventions
- OTHER Care pathway
Study Locations (1)
Wisconsin
- Children's Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,328 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT05373771 shows while recruiting
NCT05373771 is an interventional study that assigns participants to a tested intervention. Its 5,328 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (279% higher).
The record links to 1 condition, with Sickle Cell Crisis appearing as the primary indexed condition, and to 1 intervention - of which Care pathway is the first listed.
NCT05373771 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05373771 about?
NCT05373771 is a clinical study titled "Sickle Cell Improvement: Enhancing Care in the Emergency Department". Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, an...
What is the current status of trial NCT05373771?
This trial is currently recruiting. It is a NA study. The enrollment target is 5,328 participants. The study started on 2021-09-01. Estimated completion is 2027-08-31.
What conditions does trial NCT05373771 study?
This clinical trial studies the following conditions: Sickle Cell Crisis.
What interventions are being tested in trial NCT05373771?
The interventions under investigation include: Care pathway (OTHER).
Who is sponsoring clinical trial NCT05373771?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05373771 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05373771's enrollment target sits among peer trials
5,328 24th of 2000 higher than 1,977 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI